{
    "clinical_study": {
        "@rank": "93977", 
        "acronym": "APAP", 
        "arm_group": [
            {
                "arm_group_label": "normal weight patients", 
                "arm_group_type": "Experimental", 
                "description": "normal weight patients receiving acetaminophen 2 g instead of 1 g"
            }, 
            {
                "arm_group_label": "mobidly obese patients", 
                "arm_group_type": "Experimental", 
                "description": "morbidly obese patients receiving acetaminophen 2 g instead of 1 g"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate the pharmacokinetics of acetaminophen in morbidly obese patients\n      versus normal weight patients. Specifically the different metabolic pathways of\n      acetaminophen in morbidly obese adults will be investigated; glucuronidation, sulphation and\n      CYP2E1 (cytochrome P450 2E1) oxidation"
        }, 
        "brief_title": "Pharmacokinetics of Acetaminophen in Morbidly Obese Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Morbid Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Obesity, Morbid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria for morbidly obese patients:\n\n          -  BMI > 40 kg/m2 undergoing bariatric surgery.\n\n          -  Patients between 18 - 60 years old\n\n          -  ASA physical classification of II or III\n\n          -  All racial and ethnic groups will be included\n\n        Inclusion criteria for control group:\n\n          -  BMI between 18 and 25 kg/m2 undergoing general surgery\n\n          -  Patients between 18 - 60 years old\n\n          -  ASA (American Society of Anesthesiology) physical classification of I, II or III\n\n          -  All racial and ethnic groups will be included\n\n        Exclusion criteria for all study arms:\n\n          -  Renal insufficiency\n\n          -  Liver disease\n\n          -  Patients with Gilbert-Meulengracht syndrome\n\n          -  Chronic alcohol intake or use of alcohol within last 72 hours\n\n          -  Pregnancy or breastfeeding\n\n          -  Patients who are treated with drugs know to affect CYP2E1 and UGT (UDP\n             glucuronosyltransferase)\n\n          -  Diabetes mellitus type II patients\n\n          -  Smoking\n\n          -  Acetaminophen intake before the study (24 hours before study)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764555", 
            "org_study_id": "APAP study", 
            "secondary_id": "2012-000956-32"
        }, 
        "intervention": {
            "arm_group_label": [
                "normal weight patients", 
                "mobidly obese patients"
            ], 
            "intervention_name": "acetaminophen 2 g", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acetaminophen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "contact": {
                "email": "a.van.rongen@antoniusziekenhuis.nl", 
                "last_name": "Anne van Rongen, MSc", 
                "phone": "030-6093500"
            }, 
            "facility": {
                "address": {
                    "city": "Nieuwegein", 
                    "country": "Netherlands", 
                    "zip": "3435CM"
                }, 
                "name": "St. Antonius Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Morbidly Obese Patients", 
        "overall_contact": {
            "email": "a.van.rongen@antoniusziekenhuis.nl", 
            "last_name": "Anne van Rongen, MSc", 
            "phone": "030-6093500"
        }, 
        "overall_official": {
            "affiliation": "St. Antonius Hospital", 
            "last_name": "Catherijne Knibbe, Prof dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Clearance (total, glucuronidation, sulphation, CYP2E1 oxidation and unchanged) of acetaminophen in morbidly obese patients in comparison with normal weight patients.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Volume of distribution of acetaminophen in morbidly obese patients in comparison with normal weight patients.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764555"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Antonius Hospital", 
            "investigator_full_name": "Catherijne Knibbe", 
            "investigator_title": "Prof. dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Difference in clearance (total, glucuronidation, sulphation, CYP2E1 oxidation) of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.", 
                "safety_issue": "No", 
                "time_frame": "8 hours"
            }, 
            {
                "measure": "Difference in volume of distribution of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.", 
                "safety_issue": "No", 
                "time_frame": "8 hours"
            }, 
            {
                "measure": "Liver function tests in morbidly obese patients in comparison with normal weight patients.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "St. Antonius Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Antonius Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}